康诺亚-B股票讨论区

CM310的III期注册性临床试验结果显示出优于安慰剂组的显著疗效，包括湿疹面积和严重程度指数的改善，研究者整体评分法评分的提高，以及瘙痒控制和生活质量的改善。这可能对康诺亚-B的股价产生积极影响。

重点：
1. 恒生指数在前两周（2023/05/22至2023/06/02）下跌了2.57%，所有12个恒生指数行业都出现了下跌。其中，恒生医疗保健板块下跌了1.51%，表现优异，超出恒生指数1.06个百分点，位列12个恒生指数行业第三
2. 5月22日，高端抗体药百济神州

$康诺亚-B (02162.HK)$ Short-term share prices are hard to pin down. I remember that in 19 years, Cinda was over 20 billion for a whole year and broke 100 billion in 20 years. In November last year, Kangfang fell to more than 10 billion yuan and rose back to 30 billion yuan in a month or two. In April this year, Corning & Jerry's was only more than 8 billion yuan at its worst, and broke 20 billion yuan in one or two months. Konoya is now left time, firmly optimistic about the first half of next year to stand at $20 billion.